S-adenosylmethionine blocks osteosarcoma cells proliferation and invasion in vitro and tumor metastasis in vivo: Therapeutic and diagnostic clinical applications

Cancer Medicine

Volumn 4, Issue 5, 2015, Pages 732-744

  Parashar, Surabhi ^a   Cheishvili, David ^a   Arakelian, Ani ^a   Hussain, Zahid ^a   Tanvir, Imrana ^b   Khan, Haseeb Ahmed ^b   Szyf, Moshe ^a   Rabbani, Shafaat A ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b FATIMA MEMORIAL HOSPITAL   (Pakistan)

Author keywords

DNA methylation; Gene expression; Osteosarcoma; Patients; Signaling pathways; Tumor progression

Indexed keywords

ADENOSINE DERIVATIVE; ANTIMETASTATIC AGENT; ANTIMITOTIC AGENT; HOMOCYSTINE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; S ADENOSYLHOMOCYSTINE; S ADENOSYLMETHIONINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DNA METHYLATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LM 7 CELL LINE; LUNG METASTASIS; MALE; METASTASIS INHIBITION; MG 63 CELL LINE; MIGRATION INHIBITION; MOUSE; NONHUMAN; OSSIFICATION; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TIBIA; TREATMENT RESPONSE; WOUND HEALING; ANIMAL; BIOPSY; BONE NEOPLASMS; CELL CYCLE; CELL MOTION; DRUG EFFECTS; EPIGENETICS; GENE EXPRESSION REGULATION; GENETICS; METASTASIS; PATHOLOGY; TUMOR CELL LINE; TUMOR STEM CELL ASSAY;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOPSY; BONE NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DNA METHYLATION; EPIGENOMICS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; NEOPLASM METASTASIS; OSTEOSARCOMA; S-ADENOSYLMETHIONINE; TUMOR STEM CELL ASSAY;

EID: 84944889296     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.386     Document Type: Article

References (49)

1. Rainusso, N., L. L. Wang, and J. T. Yustein . 2013. The adolescent and young adult with cancer: state of the art-bone tumors. Curr. Oncol. Rep. 15:296-307.
2. Ottaviani, G., and N. Jaffe . 2009. The epidemiology of osteosarcoma. Cancer Treat. Res. 152:3-13.
3. Meyers, P. A., G. Heller, J. Healey, A. Huvos, J. Lane, R. Marcove, et al. 1992. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J. Clin. Oncol. 10:5-15.
4. Ferrari, S., A. Briccoli, M. Mercuri, F. Bertoni, M. Cesari, A. Longhi, et al. 2006. Late relapse in osteosarcoma. J. Pediatr. Hematol. Oncol. 28:418-422.
5. Bielack, S. S., B. Kempf-Bielack, G. Delling, G. U. Exner, S. Flege, K. Helmke, et al. 2002. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1, 702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J. Clin. Oncol. 20:776-790.
6. Wang, L. L. 2005. Biology of osteogenic sarcoma. Cancer J. 11:294-305.
7. Ferguson, W. S., and A. M. Goorin . 2001. Current treatment of osteosarcoma. Cancer Invest. 19:292-315.
8. Marina, N., M. Gebhardt, L. Teot, and R. Gorlick . 2004. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9:422-441.
9. Munoz Villa, A., G. Ocete, M. L. Aymerich, S. Maldonado, E. Otheo, M. Calvo, et al. 1996. Preoperative and postoperative chemotherapy of osteogenic sarcoma of the limbs in children. Med. Clin. (Barc.) 107:161-164.
10. Szuhai, K., A.-M. Cleton-Jansen, P. C. W. Hogendoorn, and J. V. M. G. Bovee . 2012. Molecular pathology and its diagnostic use in bone tumors. Cancer Genet. 205:193-204.
11. Rao-Bindal, K., and E. S. Kleinerman . 2011. Epigenetic regulation of apoptosis and cell cycle in osteosarcoma. Sarcoma 2011:679457.
12. Esteller, M. 2007. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat. Rev. Genet. 8:286-298.
13. Das, P. M., K. Ramachandran, J. Vanwert, L. Ferdinand, G. Gopisetty, I. M. Reis, et al. 2006. Methylation mediated silencing of TMS1/ASC gene in prostate cancer. Mol. Cancer. 5:28.
14. Al-Romaih, K., B. Sadikovic, M. Yoshimoto, Y. Wang, M. Zielenska, and J. A. Squire . 2008. Decitabine-induced demethylation of 5' CpG island in GADD45A leads to apoptosis in osteosarcoma cells. Neoplasia 10:471-480.
15. Cote, G. M., and E. Choy . 2013. Role of epigenetic modulation for the treatment of sarcoma. Curr. Treat. Options Oncol. 14:454-464.
16. Horsthemke, B. 2006. Epimutations in human disease. Curr. Top. Microbiol. Immunol. 310:45-59.
17. Lee, C. J., J. Evans, K. Kim, H. Chae, and S. Kim . 2014. Determining the effect of DNA methylation on gene expression in cancer cells. Methods Mol. Biol. 1101:161-178.
18. Stefanska, B., J. Huang, B. Bhattacharyya, M. Suderman, M. Hallett, Z. G. Han, et al. 2011. Definition of the landscape of promoter DNA hypomethylation in liver cancer. Cancer Res. 71:5891-5903.
19. Connolly, R., and V. Stearns . 2012. Epigenetics as a therapeutic target in breast cancer. J. Mammary Gland Biol. Neoplasia 17:191-204.
20. Chik, F., and M. Szyf . 2011. Effects of specific DNMT gene depletion on cancer cell transformation and breast cancer cell invasion; toward selective DNMT inhibitors. Carcinogenesis 32:224-232.
21. Ateeq, B., A. Unterberger, M. Szyf, and S. A. Rabbani . 2008. Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo. Neoplasia 10:266-278.
22. Szyf, M., P. Pakneshan, and S. A. Rabbani . 2004. DNA demethylation and cancer: therapeutic implications. Cancer Lett. 211:133-143.
23. Boal, A. K., T. L. Grove, M. I. McLaughlin, N. H. Yennawar, S. J. Booker, and A. C. Rosenzweig . 2011. Structural basis for methyl transfer by a radical SAM enzyme. Science 332:1089-1092.
24. Pakneshan, P., M. Szyf, R. Farias-Eisner, and S. A. Rabbani . 2004. Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis. J. Biol. Chem. 279:31735-31744.
25. Shukeir, N., P. Pakneshan, G. Chen, M. Szyf, and S. A. Rabbani . 2006. Alteration of the methylation status of tumor-promoting genes decreases prostate cancer cell invasiveness and tumorigenesis in vitro and in vivo. Cancer Res. 66:9202-9210.
26. Kinsel, L. B., E. Szabo, G. L. Greene, J. Konrath, G. S. Leight, and K. S. McCarty, Jr. 1989. Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. Cancer Res. 49:1052-1056.
27. Mazières, J., W. Brugger, F. Cappuzzo, P. Middel, A. Frosch, I. Bara, et al. 2013. Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: re-analysis of the SATURN study. Lung Cancer 82:231-237.
28. Rabbani, S. A., A. Arakelian, and R. Farookhi . 2013. LRP5 knockdown: effect on prostate cancer invasion growth and skeletal metastasis in vitro and in vivo. Cancer Med. 2:625-635.
29. Rabbani, S. A., B. Ateeq, A. Arakelian, M. L. Valentino, D. E. Shaw, L. M. Dauffenbach, et al. 2010. An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo. Neoplasia 12:778-788.
30. Rabbani, S. A., M. L. Valentino, A. Arakelian, S. Ali, and F. Boschelli . 2010. SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis. Mol. Cancer Ther. 9:1147-1157.
31. Khalili, P., A. Arakelian, G. Chen, M. L. Plunkett, I. Beck, G. C. Parry, et al. 2006. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol. Cancer Ther. 5:2271-2280.
32. Khalili, P., A. Arakelian, G. Chen, G. Singh, and S. A. Rabbani . 2005. Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer. Oncogene 24:6657-6666.
33. Graat, H. C., V. W. van Beusechem, F. H. Schagen, M. A. Witlox, E. S. Kleinerman, M. N. Helder, et al. 2008. Intravenous administration of the conditionally replicative adenovirus Ad5-Delta24RGD induces regression of osteosarcoma lung metastases. Mol. Cancer. 7:9.
34. Rastelli, L., M. L. Valentino, M. C. Minderman, J. Landin, U. M. Malyankar, M. K. Lescoe, et al. 2011. A KDR-binding peptide (ST100, 059) can block angiogenesis, melanoma tumor growth and metastasis in vitro and in vivo. Int. J. Oncol. 39:401-408.
35. Yau, C., L. Esserman, D. H. Moore, F. Waldman, J. Sninsky, and C. C. Benz . 2010. A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res. 12:R85.
36. Valk-Lingbeek, M. E., S. W. Bruggeman, and M. van Lohuizen . 2004. Stem cells and cancer; the polycomb connection. Cell 118:409-418.
37. Gil, J., D. Bernard, and G. Peters . 2005. Role of polycomb group proteins in stem cell self-renewal and cancer. DNA Cell Biol. 24:117-125.
38. Tripurani, S. K., R. W. Cook, K. W. Eldin, and S. A. Pangas . 2013. BMP-specific SMADs function as novel repressors of PDGFA and modulate its expression in ovarian granulosa cells and tumors. Oncogene 32:3877-3885.
39. Baylin, S. B., M. Esteller, M. R. Rountree, K. E. Bachman, K. Schuebel, and J. G. Herman . 2001. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum. Mol. Genet. 10:687-692.
40. Detich, N., S. Hamm, G. Just, J. D. Knox, and M. Szyf . 2003. The methyl donor S-adenosylmethionine inhibits active demethylation of DNA: a candidate novel mechanism for the pharmacological effects of S-adenosylmethionine. J. Biol. Chem. 278:20812-20820.
41. Goel, H. L., and A. M. Mercurio . 2013. VEGF targets the tumour cell. Nat. Rev. Cancer 13:871-882.
42. Kwaan, H. C., A. P. Mazar, and B. J. McMahon . 2013. The apparent uPA/PAI-1 paradox in cancer: more than meets the eye. Semin. Thromb. Hemost. 39:382-391.
43. Wakefield, L. M., and C. S. Hill . 2013. Beyond TGFbeta: roles of other TGFbeta superfamily members in cancer. Nat. Rev. Cancer 13:328-341.
44. Chimge, N. O., and B. Frenkel . 2013. The RUNX family in breast cancer: relationships with estrogen signaling. Oncogene 32:2121-2130.
45. Shiou, S. R., P. K. Datta, P. Dhawan, B. K. Law, J. M. Yingling, D. A. Dixon, et al. 2006. Smad4-dependent regulation of urokinase plasminogen activator secretion and RNA stability associated with invasiveness by autocrine and paracrine transforming growth factor-beta. J. Biol. Chem. 281:33971-33981.
46. Akech, J., J. J. Wixted, K. Bedard, M. van der Deen, S. Hussain, T. A. Guise, et al. 2010. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 29:811-821.
47. Pockwinse, S. M., K. P. Kota, A. J. Quaresma, A. N. Imbalzano, J. B. Lian, A. J. van Wijnen, et al. 2011. Live cell imaging of the cancer-related transcription factor RUNX2 during mitotic progression. J. Cell. Physiol. 226:1383-1389.
48. Boonjaraspinyo, S., Z. Wu, T. Boonmars, S. Kaewkes, W. Loilome, P. Sithithaworn, et al. 2012. Overexpression of PDGFA and its receptor during carcinogenesis of Opisthorchis viverrini-associated cholangiocarcinoma. Parasitol. Int. 61:145-150.
49. Martinho, O., A. Longatto-Filho, M. B. Lambros, A. Martins, C. Pinheiro, A. Silva, et al. 2009. Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas. Br. J. Cancer 101:973-982.